5328902026-04-012026-06-305328902026-04-012026-06-30in-capmkt:OtherExpenses1Memberiso4217:INRiso4217:INRxbrli:shares532890TAKENOTLISTEDINE142I01023TAKE LimitedMain BoardEquity2026-04-012027-03-312026-08-112026-08-04INRLakhsQuarterlyFirst quarterSingle segmentLife Sciences2026-08-1117:00:002026-08-1118:00:00Not applicablefalsefalseNot Applicable2026-04-012026-06-30UnauditedStandalone119690000132780001329680000119692000074000070002000284400012328500096830000968300000009683000000096830000968300014793400010.070.07000.070.07Notes: <br /> <br /> 1. The Unaudited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026 were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on August 11, 2026. <br /> <br /> 2. The Statutory Auditors of the Company have carried out a Limited Review of the financial results for the quarter ended June 30, 2026 in compliance with terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. <br /> <br /> 3. The statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013, and other recognised accounting practices and policies to the extent applicable. <br /> <br /> 4. Previous period figures have been regrouped and reclassified wherever necessary. <br /> <br /> 5. As the Company’s business activity falls within a single primary business segment, the disclosure requirements under Ind AS 108 ‘Operating Segments’ are not applicable. <br /> <br /> 6. The name of the Company has been changed from “TAKE Solutions Limited” to “TAKE Limited” with effect from June 25, 2026, pursuant to the Certificate of Incorporation issued by the Ministry of Corporate Affairs. <br /> Other expenses2844000